Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
DocMorris ( (CH:DOCM) ) just unveiled an announcement.
DocMorris has reported a 9.5% increase in total revenue for the first nine months of 2025, driven by significant growth in both Rx and Non-Rx sales. The company has launched the AI-based DocMorris Health Companion, expanded its executive board, and is focusing on sustainable growth and profitability, with plans to achieve EBITDA breakeven by 2026. The strategic use of AI and streamlining of management structures are central to its operational efficiency and market positioning.
The most recent analyst rating on (CH:DOCM) stock is a Hold with a CHF6.00 price target. To see the full list of analyst forecasts on DocMorris stock, see the CH:DOCM Stock Forecast page.
More about DocMorris
DocMorris operates in the healthcare industry, focusing on pharmaceutical products and digital health services. The company is known for its innovative use of AI in healthcare, offering products like the DocMorris Health Companion, and has a strong market presence in Europe, particularly in Germany.
Average Trading Volume: 405,974
Technical Sentiment Signal: Sell
Current Market Cap: CHF294.1M
See more insights into DOCM stock on TipRanks’ Stock Analysis page.